JP2005525329A - 向精神薬とセレンから成る配合物 - Google Patents

向精神薬とセレンから成る配合物 Download PDF

Info

Publication number
JP2005525329A
JP2005525329A JP2003565495A JP2003565495A JP2005525329A JP 2005525329 A JP2005525329 A JP 2005525329A JP 2003565495 A JP2003565495 A JP 2003565495A JP 2003565495 A JP2003565495 A JP 2003565495A JP 2005525329 A JP2005525329 A JP 2005525329A
Authority
JP
Japan
Prior art keywords
selenium
drug
day
daily dose
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525329A5 (enExample
Inventor
ヴァダディ，クリシュナラオ，シタランラオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laxdale Ltd
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Publication of JP2005525329A publication Critical patent/JP2005525329A/ja
Publication of JP2005525329A5 publication Critical patent/JP2005525329A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2003565495A 2002-02-07 2003-02-04 向精神薬とセレンから成る配合物 Pending JP2005525329A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202900.7A GB0202900D0 (en) 2002-02-07 2002-02-07 Novel formulations of drugs
PCT/GB2003/000490 WO2003066071A1 (en) 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium

Publications (2)

Publication Number Publication Date
JP2005525329A true JP2005525329A (ja) 2005-08-25
JP2005525329A5 JP2005525329A5 (enExample) 2005-12-22

Family

ID=9930626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565495A Pending JP2005525329A (ja) 2002-02-07 2003-02-04 向精神薬とセレンから成る配合物

Country Status (8)

Country Link
US (1) US6919330B2 (enExample)
EP (1) EP1478374A1 (enExample)
JP (1) JP2005525329A (enExample)
AU (1) AU2003244454A1 (enExample)
GB (1) GB0202900D0 (enExample)
NZ (1) NZ534304A (enExample)
TW (1) TW200404558A (enExample)
WO (1) WO2003066071A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106732A (ja) * 2005-10-14 2007-04-26 Ortec Inc 細胞機能を変化させるための方法および組成物
JP2009532340A (ja) * 2006-03-29 2009-09-10 ベラコル セラピューティクス プロプライエタリー リミテッド 神経変性疾患の治療
JP2010540568A (ja) * 2007-10-03 2010-12-24 ベラコル セラピューティクス プロプライエタリー リミテッド 神経障害の処置
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7071879B2 (en) 2004-06-01 2006-07-04 Ems Technologies Canada, Ltd. Dielectric-resonator array antenna system
FR2873376B1 (fr) * 2004-07-23 2006-11-24 Tetrahedron Sas Nouveaux seleno-hydroxyacides et leurs derives, applications en nutrition, cosmetique et pharmacie
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
EP2813225B1 (en) * 2004-09-24 2017-12-13 University of Maryland, Baltimore Method of treating organophosphorous poisoning
CN101035550B (zh) * 2004-10-05 2010-05-05 爱脑备库司株式会社 用于治疗或预防精神病学症状的组合物及方法
WO2007127273A2 (en) * 2006-04-24 2007-11-08 Alltech, Inc. Methods and compositions for altering cell function
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090414A (en) * 1970-05-20 2000-07-18 Life Science Labs, Inc. Method and composition to reduce cancer incidence
SE7812170L (sv) * 1977-12-07 1979-06-08 Klippan Nv Belteslas med lett frigorbar sperr
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
US5358720A (en) 1993-10-22 1994-10-25 Koppel Richard M Treatment of arthritic conditions
HUT72422A (en) 1994-04-20 1996-04-29 Beres Export Import Rt Aquous concentrate and process for its preparation
FR2737205B1 (fr) * 1995-07-26 1997-09-12 Oreal Nouveaux derives de n,n'-di(aralkyl) n,n'-di(2-azaaralkyl) alkylene diamine et leur utilisation dans des compositions pharmaceutiques et cosmetiques
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
US6399114B2 (en) 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
ATE323479T1 (de) 2000-06-16 2006-05-15 Matthias Dr Med Rath Zusammensetzung für die verhinderung der glattmuskelkrankheiten, die ascorbat, arginin und magnesium enthält

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106732A (ja) * 2005-10-14 2007-04-26 Ortec Inc 細胞機能を変化させるための方法および組成物
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
JP2009532340A (ja) * 2006-03-29 2009-09-10 ベラコル セラピューティクス プロプライエタリー リミテッド 神経変性疾患の治療
US8920851B2 (en) 2006-03-29 2014-12-30 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
JP2010540568A (ja) * 2007-10-03 2010-12-24 ベラコル セラピューティクス プロプライエタリー リミテッド 神経障害の処置
US9415063B2 (en) 2007-10-03 2016-08-16 Velacor Therapeutics Pty Ltd. Treatment of neurological disorders

Also Published As

Publication number Publication date
NZ534304A (en) 2006-07-28
US6919330B2 (en) 2005-07-19
GB0202900D0 (en) 2002-03-27
EP1478374A1 (en) 2004-11-24
TW200404558A (en) 2004-04-01
WO2003066071A8 (en) 2006-08-17
WO2003066071A1 (en) 2003-08-14
AU2003244454A1 (en) 2003-09-02
US20030175361A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
US20230210930A1 (en) Compositions and methods for treating depression
US20160166631A1 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
US6919330B2 (en) Formulations of drugs
CN103517711A (zh) 可用于治疗脂质代谢障碍的组合物
WO2002007768A1 (en) Dietary supplement compositions
CN1758906A (zh) 改善肥胖症的组合物
AU2010206791B2 (en) A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
US6369041B2 (en) Oral combinations of hydroxocobalamin and folic acid
JPS62277325A (ja) アセトアルデヒド解毒剤
US20030194453A1 (en) Dietary supplement
US20240277750A1 (en) Compositions and methods for treating depression
CN115315199A (zh) 用于抑制认知功能下降和/或改善认知功能的组合物
JP2005220025A (ja) 経口摂取組成物
CN102114024B (zh) 预防月经期偏头痛的复方雌谷胶囊
CA3042699C (en) Compositions and methods for treating depression
Iqbal et al. Amin-ul aziz and Kashish Aziz (2016) Enteric Coated Iron Folic Acid Tablets: Compromised Efficacy at Cost of Safety
US20200206290A1 (en) Compositions including milk thistle and methods of use
CN116392476A (zh) 协同抑制胰脂肪酶的组合物及其应用
WO2011034006A1 (ja) 血液中の尿酸値を低下させるための組成物
HK1195221A (en) A multivitamin/mineral formulation to improve immunity and improve energy while addressing vitamin and mineral deficiencies
JP2008133271A (ja) 生活習慣病の予防および／または治療用組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091208